Chemistry:DLX-2270

From HandWiki

DLX-2270 is an experimental serotonin receptor modulator which is under investigation for the potential treatment of schizophrenia.[1][2][3]

It acts as a serotonin 5-HT2A receptor antagonist and serotonin 5-HT2C receptor agonist.[1][3] In contrast to conventional antipsychotics, DLX-2270 is not a dopamine D2 receptor antagonist.[1] The drug is orally active and centrally penetrant.[1] In preclinical research, DLX-2270 has psychoplastogenic effects.[1][3] It reverses hyperlocomotion and social interaction deficits induced by the NMDA receptor antagonist phencyclidine (PCP).[1] In contrast to serotonin 5-HT2A receptor agonists, DLX-2270 does not produce the head-twitch response in rodents, and hence would not be expected to be hallucinogenic in humans.[1][3]

DLX-0002700.[4]

DLX-2270 was first described in the scientific literature in 2025.[1] It is under development by Delix Therapeutics.[1] The drug has reached the preclinical research stage of development.[2] DLX-2270 is a small molecule, but its chemical structure does not yet appear to have been disclosed.[1] However, Delix Therapeutics has patented dual serotonin 5-HT2A receptor antagonists and serotonin 5-HT2C receptor agonists with psychoplastogenic effects for treatment of psychotic disorders, such as the cyclized isotryptamine and partial ergoline-like DLX-0002700.[4]

See also

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 "569. Preclinical Pharmacology of DLX-2270: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Schizophrenia". Biological Psychiatry 97 (9): S333. 2025. doi:10.1016/j.biopsych.2025.02.808. https://linkinghub.elsevier.com/retrieve/pii/S0006322325009060. Retrieved 13 May 2025. 
  2. ↑ 2.0 2.1 "Delving into the Latest Updates on DLX-2270 with Synapse". 24 January 2026. https://synapse.patsnap.com/drug/b88a05a59fde426597da8b55c78b8f90. 
  3. ↑ 3.0 3.1 3.2 3.3 Martínez, Sergio Lázaro (27 January 2026). "The Perils of Non-Hallucinogenic Claims: On the Limits of Translatability". https://open-foundation.org/non-hallucinogenic-psychedelics-htr/. "Non-Hallucinogenic Labeling and Semantic Drifts: In parallel, the label “non-hallucinogenic agonist” has often been applied in an unnecessary and overly expansive manner. For example, DLX-2270 has been described as a “non-hallucinogenic neuroplastogen” despite functioning pharmacologically as a 5-HT2A receptor antagonist with concurrent 5-HT2C agonism. This mechanism is fundamentally distinct from that of a 5-HT2A agonist and illustrates the degree to which semantic drift and marketing pressures have shaped the space." 
  4. ↑ 4.0 4.1 "Mixed serotonin receptor binders for treatment of psychotic disorders". 20 December 2024. https://patents.google.com/patent/WO2025137596A1/en. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:DLX-2270&oldid=4308760"